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Abstract
Background: Diabetes mellitus (DM) has reached epidemic proportions and is an important risk factor
for heart failure (HF). Left ventricular diastolic dysfunction (LVDD) is recognized as the earliest
manifestation of DM-induced LV dysfunction, but its pathophysiology remains incompletely understood.
We sought to evaluate the relationship between proinflammatory cytokine levels (TNF-alpha, IL-6) and
tissue Doppler derived indices of LVDD in patients with stable coronary artery disease.
Methods:  We enrolled 41 consecutive patients (mean age 65+/-10 years) submitted for coronary
angiography. Echocardiographic assessment was performed in all patients. Pulsed tissue Doppler imaging
was performed at the mitral annulus and was characterized by the diastolic early relaxation velocity Em.
Conventional transmitral flow was measured with pw-doppler. Early (E) transmitral flow velocity was
measured. LVDD was defined as E/Em ratio ≥ 15, E/Em 8-14 was classified as borderline. Plasma levels of
TNF-alpha and IL-6 were determined in all patients. A standardized oral glucose tolerance test was
performed in subjects without diabetes.
Results: Patients with E/Em ratio ≥ 15, classified as LVDD and those with E/Em ratio 8-14 (classified as
borderline) had significantly higher IL-6 (P = 0,001), TNF-alpha (P < 0,001) and NT-pro- BNP (P = 0,001)
plasma levels compared to those with normal diastolic function. TNF-alpha and IL-6 levels remains
significantly elevated after adjustment for sex, age, left ventricular ejection function, body mass index,
coronary heart disease, smoking, hypertension and diabetes mellitus with linear regression analysis.
Furthermore, in subjects LVDD or borderline LV diastolic function, 75% had diabetes or IGT, respectively.
When subjects without diabetes were excluded, both IL-6 (P = 0,006) and TNF-alpha (P = 0,002) remained
significantly elevated in subjects with E/Em ratio ≥ 15.
Conclusion: This study reveals that increased plasma levels of IL-6 and TNF-alpha were associated with
LVDD. These findings suggest a link between low-grade inflammation and the presence of LVDD. An active
proinflammatory process may be of importance in the pathogenesis of diastolic dysfunction.
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Background
Diastolic heart failure and diabetes mellitus (DM) are
contributors to mortality, hospitalization and medical
costs in health care systems worldwide. Cardiovascular
disease is the leading course of death among subjects with
diabetes, accounting for over 60% of mortality. While DM
is uniformly recognized as an important risk factor for the
development of coronary artery disease and its complica-
tions, it is less well acknowledged that DM is a powerful
and independent risk factor for the development and
prognosis of heart failure independent of coronary artery
disease (CAD) [1]. Left ventricular diastolic dysfunction
(LVDD) is considered a precursor of systolic heart failure
and diabetic cardiomyopathy [2,3] and is common in the
community and especially in diabetic patients [4,5].
There is increasing evidence that inflammation is involved
in the pathophysiology of heart failure and diabetes [6-9].
Most recent studies have linked insulin- resistance with
TNF-α and IL6 and those studies have shown that a meas-
ure of proinflammation is predictive for type 2 diabetes.
Furthermore, increased circulating concentrations of IL-6
and TNF-α were found in Type 2 DM and impaired glu-
cose tolerance [10-12].
Little information is available about whether inflamma-
tion is involved in the development of LVDD as the earli-
est stage in the development of heart failure.
Advantages in echocardiographic techniques have made it
possible to comprehensively access LV diastolic function
[13]. Tissue Doppler imaging is a simple, reproducible
and widely available noninvasive tool for the assessment
of alterations of left ventricular (LV) diastolic function. A
recent guideline of the American Society of Echocardiog-
raphy (ASE) implemented TDI techniques as the basic
principle to diagnose diastolic heart failure [14].
This study was designed to explore the possible associa-
tion between LVDD and proinflammation reflected by IL-
6 and TNF-α levels in subjects with stable coronary artery
disease.
Methods
The present study is a substudy of a larger survey in which
we investigated the relationship between diastolic dys-
function and cardiovascular autonomic neuropathy in
150 patients submitted for coronary angiography.
41 subjects submitted for coronary angiography for stable
or suspected coronary artery disease (CAD) were consecu-
tively enrolled in this substudy. The protocol was
approved by the local ethics committee, and signed
informed consent was obtained from all patients. We
excluded patients with hypertrophic obstructive cardio-
myopathy, moderate-to-severe valvular disease, uncon-
trolled hypertension, atrial fibrillation or other severe
arrhythmias. Oral glucose tolerance tests (OGTTs) were
carried out according to the World Health Organization
protocol as previously described. Echocardiography for
the diagnosis of diastolic dysfunction was performed on a
Philips IE33 Ultrasound System machine. Conventional
transmitral flow was measured with pw-doppler. Early
(E), atrial (A) transmitral peak flow velocities and the
ratio (E/A) were measured. Pulsed wave TDI was per-
formed at the junction of the LV wall with the medial
mitral annulus end-expiratory. Early diastolic velocity
(Em) was recorded. Ratio of E/Em was calculated. The E/
Em ratio was used to classify LVDD. LVDD was defined as
E/Em ratio ≥ 15, borderline diastolic function as E/Em
between 8-14 and normal diastolic function as E/Em < 8
according to the guidelines of the ASE [14].
Interleukin-6 and TNF-α were measured with high-sensi-
tivity enzyme linked immunoassay [14]. NT-pro BNP was
measured by a commercial available Immuno-Assay
(Roche Diagnostics®).
Autonomic nervous function was assessed according to
the guidelines of German diabetes association. Spectral
analysis with Fourier transformation was performed.
Therefore a commercially computer program (VariaCar-
dio TF4-System) was used. The following tests were per-
formed: (1) coefficient of variation of R-R intervals at rest,
(2) spectral power in the very-low-frequency band, (3)
spectral power in the LF band, (4) HRV during deep
breathing, (5) maximum/minimum 30:15 ratio, (6) val-
salva ratio, (7) postural change in systolic blood pressure.
CAN is defined as the presence of ≥ 3 abnormalities
among these 7 parameters.
Statistical analysis
All analyses were performed using SPSS statistical soft-
ware (SPSS 17.0, Chicago, IL). The data are presented as
mean +- SD unless otherwise specified. A p value ≤ 0.05
was considered statistically significant. Comparison
among the 2 groups of subjects for various parameters was
performed by 1-way analysis of variance (ANOVA or t-
test) when appropriate. Pearson's linear correlation coef-
ficients were calculated for pairs of continuous variables,
Spearman's correlations coefficient was used when data
were not normally distributed. We first analyzed associa-
tions without any adjustments and then with adjustments
for potential confounders by multiple linear regression
for continuous and logistic regression for categorical vari-
ables.Cardiovascular Diabetology 2009, 8:58 http://www.cardiab.com/content/8/1/58
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Results
Demographics and clinical variables
The demographic variables of subjects with normal, bor-
derline and increased E/Em ratio are shown in Figure 1.
Subjects with E/Em > 15 were significantly older with a
higher prevalence of DM. The prevalence of coronary
heart disease, systolic dysfunction and hypertension as
possible confounders contributing to diastolic dysfunc-
tion was similar between the groups.
Glucose tolerance test
In subjects without DM, an oGTT was performed. 21
(29%) of patients enrolled in the study had a history of
diabetes. The oGTT showed impaired fasting glucose
(IGT) or new detected Diabetes (NDM) in 32 (63%) of
the included patients, only 11 (27%) of subjects enrolled
in the study had normal glucose metabolism (NGT). In
subjects with E/Em ratio ≥ 15, no patient was found with
NGT. 16,7% had IGT or NDM and 66,7% known diabe-
tes, respectively. Fasting glucose was 111 mg/dl in subjects
with E/Em ratio ≥ 15 vs. 92 mg/dl and 90 mg/dl in those
with borderline or normal E/Em ratio (P = 0,1), whereas
HbA1c was 6,9%, 6,2% and 6,1%, respectively (P = 0,3).
Proinflammatory cytokines and LVDD
The mean Em velocity was 8,4 cm/s in subjects with E/Em
ratio < 8, 7,0 cm/s in those with E/Em ratio 8-15 and 5,3
cm/s in those with E/Em ratio ≥ 15, respectively.
E/Em ratio was positively correlated with TNF-α levels (r
= 0,34, P = 0,05, Spearman-Test). In the post-hoc analysis,
patients with E/Em ratio > 15, classified as LVDD, had sig-
nificantly higher IL-6 (7,9 pg/ml vs. 3,4 pg/ml; P = 0,001),
TNF-α (7,2 pg/ml vs. 3,1 pg/ml P < 0,001) compared to
those with normal diastolic function (E/Em < 8; figure
2and 3). There was no statistically significant difference
between the borderline group and those with normal
diastolic dysfunction (P > 0,5). TNF-α (B = 1,7, P = 0,01)
and IL-6 (B = 1,51; P = 0,04) levels remains significantly
elevated after adjustment for sex, age, left ventricular ejec-
tion function, body mass index, coronary heart disease,
smoking, hypertension and diabetes mellitus with linear
regression analysis. When subjects without diabetes were
excluded, both IL-6 (P = 0,006) and TNF-alpha (P =
0,002) remained significantly elevated in subjects with E/
Em ratio ≥ 15.
Demographics and clinical variables Figure 1
Demographics and clinical variables. Demographics and clinical variables plotted against E/Em ratio. CAN = cardiovascu-
lar autonomic neuropathy, BMI = body mass index, CAD = coronary artery disease, MI = myocardial infarction, DM = Diabetes 
mellitus. * = significant (P < 0,05). # = no history of aortocoronary bypass surgery.
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Cardiovascular autonomic neuropathy (CAN)
New detected cardiovascular autonomic neuropathy
(CAN+) was found in 22% of the study group. Although
statistically not significant, 60% of subjects with diastolic
dysfunction defined as E/Em ratio ≥ 15 were found CAN+,
whereas only 9% of subjects with normal left ventricular
diastolic function were CAN+. In the subgroup with bor-
derline diastolic function, 20% were diagnosed as CAN+.
Of note, in patients CAN+, IL6 levels were significantly
higher than in those CAN- (6,1 pg/ml vs. 3,7 pg/ml, P =
0,42). Although statistically not significant, TNF-α levels
were also numerical higher (4,4 pg/ml vs. 3,5 pg/ml, P =
0,42).
NT-pro-BNP and LVDD
NT-pro-BNP levels were significantly higher in those with
E/Em ratio > 15 compared to those with borderline E/Em
ratio or normal diastolic function (1220 pg/ml vs. 192 pg/
ml vs. 277 pg/ml, P = 0.001). In diabetics, NT-pro- BNP
levels were 608 pg/ml vs. 229 pg/ml in non diabetics (P =
0,06).
Discussion
We were able to demonstrate that LVDD and proinflam-
matory cytokines are associated in subjects with normal
left ventricular systolic function. In particular increased
plasma levels TNF-α and IL-6 seem to be correlated with
impaired LVDD and more advanced left ventricular
diastolic dysfunction. These data provide clinically impor-
tant information on systemic immune abnormalities in
subjects with LVDD. The Framingham Heart Study was
the first to demonstrate an increased risk of heart failure
in patients with diabetes [1]. Since then, additional stud-
ies, including SOLVD [15] and HOPE [16], have identi-
fied diabetes as a major risk factor for the development of
heart failure. Conversely, the presence of heart failure was
identified as a possible risk factor for diabetes [17]. Sev-
eral studies have demonstrated evidence for preclinical
left ventricular diastolic dysfunction (LVDD) as the first
manifestation of myocardial involvement in diabetic
patients [3]. Although myocardial changes can be
detected with echocardiography, even before the onset of
hemodynamic abnormalities in subjects with normal
conventional echocardiography, LVDD is often not diag-
nosed in clinical practice. On the other hand, there is
increasing evidence that inflammation is involved in the
E/Em ratio and IL-6 levels Figure 2
E/Em ratio and IL-6 levels. IL-6 levels are significantly elevated in subjects with LVDD. E = Early mitral inflow velocity, Em = 
early mitral tissue relaxation velocity.
p = 0,001Cardiovascular Diabetology 2009, 8:58 http://www.cardiab.com/content/8/1/58
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pathophysiology of heart failure and diabetes [6-9].
Inflammation has become one of the central themes in
the pathogenesis of systolic heart disease over the past
decade. So far there have been few data on participation
of inflammatory factors in the development of diastolic
dysfunction.
It has been demonstrated that IL-6 shows cardiodepres-
sive properties [18]. In patients with systolic heart failure,
IL-6 and TNF-α are associated with functional NYHA class
[8]. Furthermore, IL-6 and TNF-α have been shown to be
independent predictors of mortality in heart failure [19].
On the other hand, a recent study which followed patients
with symptomatic systolic heart failure, E/Em ratio was
associated with an increased risk of death or heart trans-
plantation. A E/Em ratio > 17 had a mortality of approxi-
mately 40% vs. 5% in those with an E/Em ratio of less
than 17 (p < 0,001) [20]. From at al. demonstrated that
there is an association between duration of DM and
LVDD and that an increasing E/Em ratio is associated with
all-cause mortality in diabetic patients [21]. In this study,
duration of DM ≥ 4 years was correlated with significant
LV diastolic dysfunction and LVDD was predictive of all-
cause mortality independent of hypertension and CAD.
Recently Mogelvang et colleagues showed that in the gen-
eral population, LVDD by TDI is a powerful and inde-
pendent predictor of death, even in the subgroup with
normal conventional echocardiography [22]. Focusing on
the elderly subjects, who are prone for diabetes and its
complications, diastolic dysfunction is an independent
predictor of cardiovascular events [23]. Therefore, we
speculate that the association of elevated proinflamma-
tory cytokines with LVDD might put the patients at higher
risk for the progression of symptomatic diabetic cardio-
myopathy.
Proinflammatory cytokines are capable of modulating
cardiovascular function by various mechanisms. It is now
known that virtually every nucleated cell type in the myo-
cardium, including the cardiac myocyte, is able to secrete
proinflammatory cytokines in response to various myo-
cardial damage or stressors. The expression of these
E/Em ratio and TNF-α levels Figure 3
E/Em ratio and TNF-α levels. TNF-α levels are significantly elevated in subjects with LVDD. E = Early mitral inflow velocity, 
Em = early mitral tissue relaxation velocity.
p <  0,001Cardiovascular Diabetology 2009, 8:58 http://www.cardiab.com/content/8/1/58
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cytokines can occur in absence of systemic immune acti-
vation.
They partly act in a negative inotropic manner and cause
changes in turnover of the extracellular matrix resulting in
myocardial fibrosis. The proinflammatory cytokine TNF-
α induces cardiodepressive effects and causes apoptosis
[24]. The development of progressive cardiomyocyte
apoptosis plays a critical role on the left ventricular geom-
etry and the adverse cardiac remodeling that occurs in the
setting of sustained inflammation.
There are some limitations in the present study. The con-
sensus paper of the ESC [25] deals with the term diastolic
heart failure, referring to subjects with heart failure. In our
study, diastolic dysfunction was defined in asymptomatic
patients using TDI techniques. Nevertheless, TDI is the
most sensitive and widely available echocardiographic
tool for the assessment of LV diastolic function [14]. Fur-
thermore, the fact that Em- velocity and E/Em are highly
correlated with age might impair their predictive abilities
in high risk population like ours in which age had an
impact on the risk of cardiovascular and diabetes- related
complications.
Moreover, we did not measure LA volume index and pul-
monary vein velocities. These additional echo data might
have been of interest especially in the cohort with E/Em
ratio 8-14.
Conclusion
Our study shows for the first time, to the best of our
knowledge, a relationship between proinflammatory
cytokines and abnormalities of diastolic performance in
patients without clinical heart failure. The development of
diastolic dysfunction and its possible sequelae diabetic
cardiomyopathy is likely to be multifactorial, with puta-
tive mechanism including metabolic disturbances, insulin
resistance, myocardial fibrosis, endothelial dysfunction,
autonomic dysfunction and myocyte damage. Proinflam-
matory cytokines are involved in most if not all of these
pathophysiological changes and might be a link between
these abnormalities. At present, it is not clear which mech-
anism can explain the association between diastolic
abnormalities and IL-6 and TNF-α-levels. The relationship
between LV diastolic performance and the activation of
immunoinflammatory system should be studied more
thoroughly in the future both on experimental and clini-
cal grounds.
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